Skip to main content
Download PDF

Red blood cell distribution width is associated with sarcopenia risk in early-stage non-small cell lung cancer

BMC Cancer volume 24, Article number: 95 (2024) Cite this article

Abstract

Background

Sarcopenia has received increasing attention in non-small cell lung cancer (NSCLC). Red blood cell distribution width (RDW) is a significant component of the complete blood count and indicates the heterogeneity of erythrocyte volume. Little information is known about RDW in relation to sarcopenia in early-stage (IA-IIIA) NSCLC. The purpose of the present study was to investigate the association between RDW and sarcopenia risk in early-stage NSCLC patients.

Methods

This study included 378 patients with pathologically confirmed stage IA-IIIA NSCLC. Sarcopenia was defined by measuring the skeletal muscle index (SMI) at the eleventh thoracic vertebra level. The maximum Youden index on the receiver operating characteristic (ROC) curve was used to estimate the cutoff value for RDW to predict sarcopenia. Logistic regression analyses were carried out to assess the independent risk factors for sarcopenia in NSCLC.

Results

The ROC curve indicated that the best cutoff point for RDW to predict sarcopenia was 12.9 (sensitivity of 43.80% and specificity of 76.76%, respectively). Moreover, there were significant differences in hemoglobin (p < 0.001), comorbidities (p = 0.001), histological type (p = 0.002), and cancer stage (p = 0.032) between the high RDW and low RDW groups. Logistic regression analyses revealed that high RDW is an independent risk factor for sarcopenia in early-stage NSCLC.

Conclusion

RDW is associated with sarcopenia risk in early-stage NSCLC.

Peer Review reports

Introduction

Globally, lung cancer (LC) is one of the deadliest cancers [1]. Non-small cell lung cancer (NSCLC) is the most prevalent pathological type of LC, accounting for more than 80% of patients [2]. Researchers have found that the prognosis of LC is not only related to cancer characteristics, such as cancer stage, but also to other factors, such as sarcopenia [3]. Sarcopenia is defined as a syndrome characterized by a significant loss of muscle strength [4]. The incidence of sarcopenia in LC patients ranges from 46 to 79% [5]. Previous studies have found that in NSCLC, esophageal, bladder, and ovarian cancer, patients diagnosed with sarcopenia before surgery have a poorer prognosis than those without sarcopenia [6].

The skeletal muscle area (SMA) on CT images at the third lumbar vertebra level (L3) has been used as one of the standard methods for the diagnosis of sarcopenia because of its good correlation with systemic skeletal muscle mass [7]. However, in clinical work, chest CT does not include the image at the L3 level. Some studies have found that the SMA of the eleventh thoracic vertebra level (T11) can also be used as an indicator to reflect the skeletal muscle of the whole body [8].

Red blood cell distribution width (RDW) is one of the red blood cell (RBC) parameters, and its significance is the variation of circulating erythrocyte size [9]. Many studies have demonstrated that RDW is an independent factor in the poor prognosis of LC [10, 11]. Koma Y. et al. confirmed that RDW was correlated with the clinical stage of cancer, and the higher the RDW value, the worse the prognosis for LC patients [12]. In addition, RDW can help distinguish benign from malignant colon tumors [13].

Few studies have examined the relationship between RDW and the risk of sarcopenia in early-stage (IA-IIIA) NSCLC. Accordingly, this study aims to investigate whether RDW is associated with sarcopenia in patients with early-stage NSCLC.

Methods

Participants

We collected data about the patients who underwent lobectomy for early-stage NSCLC in the database of the Harbin Medical University Cancer Hospital from 2020 to 2021. The eligibility criteria were as follows: (i) patients over the age of 18 with pathologically confirmed NSCLC; (ii) without distant metastasis at diagnosis; (iii) patients who have not received anti-tumor therapy. Exclusion criteria: (i) patients merged with other types of tumors or hematological and autoimmune diseases; (ii) respiratory failure; (iii) insufficient clinical data or pre-operative CT images were not available. 378 patients were enrolled in this study (Fig. 1).

Fig. 1
figure 1

Flow chart for patient inclusion

Full size image

This study protocol was approved by the Ethics Committee of the Harbin Medical University Cancer Hospital. Since it was a retrospective study, informed consent from all participants was exempted.

Laboratory measurements

All patients fasted for 8 h before blood collection to measure their complete blood count, including white blood cell (WBC), platelet count (PLT), RDW, and hemoglobin. The normal RDW reference range in our laboratory is 11.5-16.5%. In addition, the neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and prognostic nutritional index (PNI) were calculated. PNI is calculated as serum albumin (ALB) (g/L) + 5×total lymphocyte count (109/L) [14].

Calculation of sarcopenia

The SMA was obtained from the CT images at T11 level by Image J software (National Institute of Health, Bethesda, MD, USA). Tissue segmentation was based on pre-established thresholds of HU in the range of − 29 to + 150 [15]. All skeletal muscle area measurements were performed by two technicians using a double-blind method, and SMA was defined as the mean of two measurements. Skeletal muscle index (SMI) was calculated by dividing the SMA by the height squared (cm2/m2). Because SMI varies by sex and race, the threshold for diagnosing sarcopenia with T11-level SMI on CT images has not been clearly defined. Sex-specific cut-off values at the lowest tertile for SMI were calculated to diagnose sarcopenia [16,17,18].

Statistical analysis

The categorical variables are expressed as numbers and percentages. Mean ± standard deviation (SD) is used to report normally distributed continuous data. For continuous variables, the two groups were divided to compare the significant difference using the Student’s t-test or the Mann-Whitney U test. For the categorical variables, the Chi-square test was used. The cutoff value for RDW to predict sarcopenia was estimated using the maximum Youden index value on the receiver operating characteristic (ROC) curve. Logistic regression analysis was performed to determine the risk factors for sarcopenia. The Pearson correlation coefficient was applied to the correlation analyses between SMI and RDW. MedCalc version 15.0, and SPSS Statistics version 26.0 were used for statistical analysis. A p-value < 0.05 represents statistical significance.

Results

According to the ROC, RDW > 12.9 is the optimal cutoff point to discriminate the risk of sarcopenia, with an AUC of 0.613 (95% confidence interval (CI) = 0.562–0.662, p = 0.0002), a sensitivity of 43.80%, and a specificity of 76.76% (Fig. 2).

Fig. 2
figure 2

An optimized cut-off value was determined for RDW using ROC curve analysis

Full size image

The baseline characteristics of NSCLC patients according to RDW status are presented in Tables 1 and 2. We observed no differences between the groups in age, gender, BMI, current smoker, pack-years, current drinker, hypertension, diabetes, tumor size, T stage, lymph node status, WBC, platelet count, NLR, PLR, PNI, and albumin. However, there were significant differences in histological type (p = 0.002), comorbidities (p = 0.001), cancer stage (p = 0.032), and hemoglobin (p < 0.001) between the two groups. Additionally, those patients with high RDW have lower SMA and SMI levels than those with low RDW. The prevalence of sarcopenia in the high-RDW group was higher than that in the low-RDW group (51.7% vs. 29.4%, p < 0.001). A significant correlation was detected between RDW and SMI (p = 0.001, r = -0.171) (Fig. 3).

Table 1 Baseline characteristics of NSCLC patients according to RDW status
Full size table
Table 2 Baseline characteristics of NSCLC patients according to RDW
Full size table
Fig. 3
figure 3

The partial correlation between RDW and SMI

Full size image

The correlation coefficient between RDW and SMI was − 0.171 (p = 0.001) (Fig. 3). After adjusting for age, sex, BMI, smoking status, alcohol consumption, hypertension, diabetes, tumor size, histological type, T stage, lymph node status, cancer stage, WBC, hemoglobin, platelet count, and albumin, the partial correlation coefficient between RDW and SMI was − 0.149 (p = 0.005).

The risk factors found to be associated with sarcopenia in the univariate logistic regression analysis were age, BMI, and RDW. These parameters were included in the multivariate logistic regression analysis model. The results identified that age (years) (odd ratio (OR) 1.033, 95% CI: 1.005–1.062, p = 0.019), BMI (OR 0.900, 95% CI: 0.839–0.966, p = 0.003), and RDW (OR 1.324, 95% CI: 1.053–1.664, p = 0.016) were the statistically significant risk factors. In particular, RDW is an independent factor for sarcopenia (Table 3).

Table 3 The risk factors for sarcopenia based on logistic regression
Full size table

Discussion

The main observation of the study was that RDW is a risk factor for sarcopenia in early-stage NSCLC. Higher RDW values were related to a higher sarcopenia risk.

The molecular mechanism by which RDW is involved in sarcopenia remains unclear. However, inflammation plays a key role in the development of sarcopenia. Previous studies have demonstrated that inflammatory responses occur during the incidence and progression of cancer [19]. Sarcopenia molecular pathways are hypothesized to be activated by a sustained overexpression of proinflammatory mediators [20]. Sarcopenia is associated with interleukin-6 (IL-6) and C-reactive protein (CRP), which are markers of inflammation [21]. CRP can also predict preoperative muscle loss [15]. In one study, it was discovered that RDW, CRP, and erythrocyte sedimentation rate are all significant indicators of inflammation. RDW has a positive correlation with CRP, tumor necrosis factor-α, and IL-6, but a negative correlation with IL-10 [22]. By reducing muscle anabolism and supply-demand balance, IL-6 has been demonstrated to cause muscular atrophy. It may also be involved in modulating muscle catabolism [23]. Increased IL-6 inhibits the maturation of RBC in the bone marrow, causing immature RBC to enter the circulation and resulting in elevated RDW [24]. A report observed that muscle strengthening activities were associated with RDW, according to a cohort analysis of 8257 US participants [25]. In patients with solid cancers, patients at either early or advanced stages had an inverse relationship between high pretreatment RDW and poor OS [26]. The correlation between increased RDW and reduced overall survival has been confirmed at any stage of NSCLC [12]. Therefore, inflammation may contribute to the link between RDW and sarcopenia in NSCLC.

Some studies have reported that age, BMI, and platelet count are risk factors for sarcopenia [27, 28]. Another study found a correlation between increased RDW and sarcopenia in general American adults [20]. These are consistent with our study. However, there was no statistical significance for some inflammatory indicators in our study, such as NLR, WBC, and PLR. This is different from the results of some previous reports. Borges TC et al. found a correlation between NLR and sarcopenia risk in cancer patients [29]. WBC was found to be independently associated with sarcopenia in a Korean study [30]. Lin J et al. demonstrated that preoperative NLR and PLR are the independent predictors of sarcopenia in gastric cancer [31]. The reasons are speculated to be related to differences in race, sample size, and criteria for inclusion and exclusion of patients.

The study has certain limitations. First, we only included patients with early-stage NSCLC, which affects the general applicability of the results. Second, the inflammatory marker, such as CRP, was not analyzed in this retrospective study. We will consider incorporating CRP into future studies to enhance the comprehensiveness of our research. Third, the possibility of over-fitting may exist due to the relatively small sample size in this study. Finally, continued investigation of the mechanism of action is warranted.

Early detection of sarcopenia in cancer is a challenge in clinical practice. RDW is a simple, cost-effective, and noninvasive diagnostic biomarker. Our study demonstrated the prognostic value of RDW in resectable NSCLC. Future prospective studies are required to confirm our findings and expand the prognostic utility of RDW to other types of cancer. Moreover, it would be interesting to investigate whether adding RDW to sarcopenia prognosis scores could improve their performance.

In conclusion, RDW is associated with sarcopenia risk in early-stage NSCLC. RDW may help to detect sarcopenia early in NSCLC patients. Exploring its underlying molecular mechanism will be helpful in seeking potential therapeutic targets.

Availability of data and materials

The data are available from the corresponding author upon request.

Abbreviations

LC:

Lung cancer

NSCLC:

Non-small cell lung cancer

SMA:

Skeletal muscle area

L3:

The third lumbar vertebra level

T11:

The eleventh thoracic vertebra level

RDW:

Red blood cell distribution width

RBC:

Red blood cell

WBC:

White blood cell

PLT:

Platelet count

NLR:

Neutrophil to lymphocyte ratio

PLR:

Platelet to lymphocyte ratio

PNI:

Prognostic nutritional index

SMI:

Skeletal muscle index

SD:

Standard deviation

ROC:

Receiver operating characteristic

CI:

Confidence interval

OR:

Odd ratio 

IL-6:

Interleukin-6

CRP:

C-reactive protein

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2018;68(6):394–424.

    Article  Google Scholar 

  2. Li C, Zhang L, Meng G, Wang Q, Lv X, Zhang J, et al. Circular RNAs: pivotal molecular regulators and novel diagnostic and prognostic biomarkers in non-small cell lung cancer. J Cancer Res Clin Oncol. 2019;145(12):2875–89.

    Article  PubMed  Google Scholar 

  3. Anderson LJ, Albrecht ED, Garcia JM. Update on management of cancer-related cachexia. Curr Oncol Rep. 2017;19(1):3.

    Article  PubMed  Google Scholar 

  4. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010;39(4):412–23.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Cortellini A, Palumbo P, Porzio G, Verna L, Giordano AV, Masciocchi C, et al. Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy. Thorac Cancer. 2018;9(12):1623–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Takamori S, Tagawa T, Toyokawa G, Shimokawa M, Kinoshita F, Kozuma Y, et al. Prognostic impact of postoperative skeletal muscle decrease in non-small cell lung cancer. Ann Thorac Surg. 2020;109(3):914–20.

    Article  PubMed  Google Scholar 

  7. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol (Bethesda Md: 1985). 2004;97(6):2333–8.

    Article  Google Scholar 

  8. Derstine BA, Holcombe SA, Ross BE, Wang NC, Su GL, Wang SC. Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. Sci Rep. 2018;8(1):11369.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Förhécz Z, Gombos T, Borgulya G, Pozsonyi Z, Prohászka Z, Jánoskuti L. Red cell distribution width in heart failure: prediction of clinical events and relationship with markers of ineffective erythropoiesis, inflammation, renal function, and nutritional state. Am Heart J. 2009;158(4):659–66.

    Article  PubMed  Google Scholar 

  10. Ma C, Wang X, Zhao R. Associations of lymphocyte percentage and red blood cell distribution width with risk of lung cancer. J Int Med Res. 2019;47(7):3099–108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Toyokawa G, Shoji F, Yamazaki K, Shimokawa M, Takeo S. Significance of the red blood cell distribution width in resected pathologic stage I nonsmall cell lung cancer. Semin Thorac Cardiovasc Surg. 2020;32(4):1036–45.

    Article  PubMed  Google Scholar 

  12. Koma Y, Onishi A, Matsuoka H, Oda N, Yokota N, Matsumoto Y, et al. Increased red blood cell distribution width associates with cancer stage and prognosis in patients with lung cancer. PLoS One. 2013;8(11):e80240.

  13. Salvagno GL, Sanchis-Gomar F, Picanza A, Lippi G. Red blood cell distribution width: a simple parameter with multiple clinical applications. Crit Rev Clin Lab Sci. 2015;52(2):86–105.

    Article  PubMed  Google Scholar 

  14. Onodera T, Goseki N, Kosaki G. [Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients]. Nihon Geka Gakkai Zasshi. 1984;85(9):1001–5.

    CAS  PubMed  Google Scholar 

  15. Okugawa Y, Toiyama Y, Yamamoto A, Shigemori T, Kitamura A, Ichikawa T, et al. Close relationship between immunological/inflammatory markers and myopenia and myosteatosis in patients with colorectal cancer: a propensity score matching analysis. JPEN J Parenter Enter Nutr. 2019;43(4):508–15.

    Article  CAS  Google Scholar 

  16. Lee JK, Park YS, Lee K, Youn SI, Won Y, Min SH, et al. Prognostic significance of surgery-induced Sarcopenia in the survival of gastric cancer patients: a sex-specific analysis. J Cachexia Sarcopenia Muscle. 2021;12(6):1897–907.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Huang CY, Yang YC, Chen TC, Chen JR, Chen YJ, Wu MH, et al. Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced-stage ovarian cancer. J Cachexia Sarcopenia Muscle. 2020;11(2):534–46.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Choi MH, Yoon SB, Lee K, Song M, Lee IS, Lee MA, et al. Preoperative sarcopenia and post-operative accelerated muscle loss negatively impact survival after resection of pancreatic cancer. J Cachexia Sarcopenia Muscle. 2018;9(2):326–34.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Singh R, Mishra MK, Aggarwal H. Inflammation, immunity, and Cancer. Mediat Inflamm. 2017;2017:6027305.

    Article  Google Scholar 

  20. Kim J, Im JS, Choi CH, Park CH, Lee JI, Son KH, et al. The association between red blood cell distribution width and sarcopenia in U.S. adults. Sci Rep. 2018;8(1):11484.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Cesari M, Penninx BW, Pahor M, Lauretani F, Corsi AM, Rhys Williams G, et al. Inflammatory markers and physical performance in older persons: the InCHIANTI study. J Gerontol A Biol Sci Med Sci. 2004;59(3):242–8.

    Article  PubMed  Google Scholar 

  22. He Y, Liu C, Zeng Z, Ye W, Lin J, Ou Q. Red blood cell distribution width: a potential laboratory parameter for monitoring inflammation in rheumatoid arthritis. Clin Rheumatol. 2018;37(1):161–7.

    Article  PubMed  Google Scholar 

  23. Tuttle CSL, Thang LAN, Maier AB. Markers of inflammation and their association with muscle strength and mass: a systematic review and meta-analysis. Ageing Res Rev. 2020;64:101185.

  24. Bester J, Pretorius E. Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity. Sci Rep. 2016;6:32188.

  25. Loprinzi PD, Loenneke JP, Abe T. The association between muscle strengthening activities and red blood cell distribution width among a national sample of U.S. adults. Prev Med. 2015;73:130–2.

    Article  PubMed  Google Scholar 

  26. Chi G, Lee JJ, Montazerin SM, Marszalek J. Prognostic value of hemoglobin-to-red cell distribution width ratio in cancer: a systematic review and meta-analysis. Biomark Med. 2022;16(6):473–82.

    Article  CAS  PubMed  Google Scholar 

  27. Wu LC, Kao HH, Chen HJ, Huang PF. Preliminary screening for Sarcopenia and related risk factors among the elderly. Medicine. 2021;100(19):e25946.

  28. Chatzipetrou V, Bégin MJ, Hars M, Trombetti A. Sarcopenia in chronic kidney disease: a scoping review of prevalence, risk factors, association with outcomes, and treatment. Calcif Tissue Int. 2022;110(1):1–31.

    Article  CAS  PubMed  Google Scholar 

  29. Borges TC, Gomes TL, Pichard C, Laviano A, Pimentel GD. High neutrophil to lymphocytes ratio is associated with Sarcopenia risk in hospitalized cancer patients. Clin Nutr. 2021;40(1):202–6.

    Article  CAS  PubMed  Google Scholar 

  30. Lee HS, Koh IH, Kim HS, Kwon YJ. Platelet and white blood cell count are independently associated with sarcopenia: a nationwide population-based study. Thromb Res. 2019;183:36–44.

    Article  CAS  PubMed  Google Scholar 

  31. Lin J, Zhang W, Huang Y, Chen W, Wu R, Chen X, et al. Sarcopenia is associated with the neutrophil/lymphocyte and platelet/lymphocyte ratios in operable gastric cancer patients: a prospective study. Cancer Manage Res. 2018;10:4935–44.

    Article  Google Scholar 

Download references

Acknowledgements

We thank all the researchers involved in this project for their generous assistance and cooperation.

Funding

This study was supported by the Harbin Medical University Cancer Hospital [Grant Number JJQN2020-05].

Author information

Author notes

  1. Qing-chun Jia and Ling Qin contributed equally to this work and share first authorship.

Authors and Affiliations

  1. Department of Internal Medicine, Harbin Medical University Cancer Hospital, Harbin Medical University, NO.150 Haping ST, Nangang District, Harbin, Heilongjiang, 150081, China

    Qing-chun Jia, Ye Niu, Le Liu, Ping-ping Liu, Ming-ming Cui & Rui-tao Wang

  2. Department of Pathology, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, Heilongjiang, 150081, China

    Ling Qin

  3. School of Computer Science and Technology, Harbin University of Science and Technology, Harbin, Heilongjiang, 150080, China

    Shi-di Miao

Authors
  1. Qing-chun Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ling Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ye Niu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Le Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ping-ping Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shi-di Miao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ming-ming Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rui-tao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization and design: M.C., R.W.; Administrative support and funding acquisition: M.C., R.W.; Provision of study materials or patients: Q.J., L.Q., Y.N.; Collection and assembly of data: L.L., P.L., S.M.; Data analysis and interpretation: Q.J., L.Q., Y.N., M.C., R.W.; Manuscript writing: Q.J., L.Q., Y.N.; Final approval of manuscript: All authors. All authors reviewed the manuscript.

Corresponding authors

Correspondence to Ming-ming Cui or Rui-tao Wang.

Ethics declarations

Ethics approval and consent to participate

This study protocol was approved by the Ethics Committee of the Harbin Medical University Cancer Hospital. The data collection and the methods used in this study were carried out in accordance with the principles outlined in the Declaration of Helsinki. The need for written informed consent was waived by the Ethics Committee of the Harbin Medical University Cancer Hospital due to the retrospective nature of the study.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jia, Qc., Qin, L., Niu, Y. et al. Red blood cell distribution width is associated with sarcopenia risk in early-stage non-small cell lung cancer. BMC Cancer 24, 95 (2024). https://doi.org/10.1186/s12885-024-11864-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12885-024-11864-z

Keywords

BMC Cancer

ISSN: 1471-2407

Contact us